Literature DB >> 19165355

Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis.

Tommaso Sanna1, Andrea Sonaglioni, Maurizio Pieroni, Antonio Dello Russo, Gemma Pelargonio, Michela Casella, Evelina Zichichi, Giuseppe La Torre, Maria Lucia Narducci, Fulvio Bellocci.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Elective electrical cardioversion is often performed in patients with persistent AF to attempt sinus rhythm (SR) restoration. However, AF recurrences are frequent after successful cardioversion and several predictors have been identified. AIM OF THE STUDY: The present study was designed to prospectively analyse the correlation between NT-pro-BNP levels and AF recurrence in consecutive patients referred for electrical cardioversion of persistent atrial fibrillation.
RESULTS: Forty consecutive patients referred for elective cardioversion of AF were enrolled in the study. Cardioversion restored sinus rhythm in 34/40 patients but 2 of them presented an early recurrence of AF before discharge. Patients were then followed for 6 months to assess AF recurrence. Cox regression analysis was performed using the parameters found predictive on univariate survival analysis (NT-pro-BNP quartiles, beta-blockers). The only independent predictor of AF recurrence on Cox-regression analysis was a level of NT-pro-BNP in the fourth quartile (HR 3.21 95%CI 1.26-8.14, p=0.014). On receiver operating curve (ROC) analysis, NT-pro-BNP levels above 1707 pg/ml had a specificity of 92% (and a sensitivity of 36%) in predicting atrial fibrillation recurrence by 6 months.
CONCLUSIONS: Baseline NT-pro-BNP levels are an independent predictor of AF recurrence at 6 months follow-up in candidates for elective direct current cardioversion.

Entities:  

Keywords:  Arrhythmia Recurrence; Cardioversion; NT-Pro-BNP; Persistent Atrial Fibrillation

Year:  2009        PMID: 19165355      PMCID: PMC2615058     

Source DB:  PubMed          Journal:  Indian Pacing Electrophysiol J        ISSN: 0972-6292


  31 in total

1.  Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion.

Authors:  Nicolas Lellouche; Romain Berthier; Armand Mekontso-Dessap; François Braconnier; Jean-Luc Monin; Anne-Marie Duval; Jean Luc Dubois-Randé; Pascal Guéret; Jérôme Garot
Journal:  Am J Cardiol       Date:  2005-06-01       Impact factor: 2.778

2.  Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion.

Authors:  Christian Perzanowski; Andrew T Ho; Alan K Jacobson
Journal:  J Electrocardiol       Date:  2005-01       Impact factor: 1.438

Review 3.  Epidemiology and natural history of atrial fibrillation: clinical implications.

Authors:  S S Chugh; J L Blackshear; W K Shen; S C Hammill; B J Gersh
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

4.  Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm.

Authors:  Luís Beck-da-Silva; Adolfo de Bold; Margaret Fraser; Kathryn Williams; Haissam Haddad
Journal:  Can J Cardiol       Date:  2004-10       Impact factor: 5.223

Review 5.  Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.

Authors:  Zaid Abassi; Tony Karram; Samer Ellaham; Joseph Winaver; Aaron Hoffman
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

6.  Factors determining long-term maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.

Authors:  Dariusz Kosior; Marian Szulc; Radosław Piatkowski; Daniel Rabczenko; Adam Torbicki; Grzegorz Opolski
Journal:  Kardiol Pol       Date:  2003-08       Impact factor: 3.108

7.  Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.

Authors:  H J Crijns; I C Van Gelder; W H Van Gilst; H Hillege; A M Gosselink; K I Lie
Journal:  Am J Cardiol       Date:  1991-08-01       Impact factor: 2.778

Review 8.  B-type natriuretic peptides: a diagnostic breakthrough for clinicians.

Authors:  Peter A McCullough; Torbjørn Omland; Alan S Maisel
Journal:  Rev Cardiovasc Med       Date:  2003       Impact factor: 2.930

9.  Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis.

Authors:  M Y Flugelman; Y Hasin; N Katznelson; M Kriwisky; A Shefer; M S Gotsman
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  4 in total

1.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

2.  The Role of NT-proBNP in the Diagnosis of Ventricular Arrhythmias in Patients with Systemic Sclerosis.

Authors:  Lucian Muresan; Ana Petcu; Crina Muresan; Mirela Rinzis; Gabriel Gusetu; Dana Pop; Dumitru Zdrenghea; Simona Rednic
Journal:  Iran J Public Health       Date:  2017-07       Impact factor: 1.429

3.  N-terminal pro-brain natriuretic peptide and atrial fibrillation.

Authors:  Jayachandran Thejus; Johnson Francis
Journal:  Indian Pacing Electrophysiol J       Date:  2009-01-07

4.  Apelin and Atrial Fibrillation: The Role in the Arrhythmia Recurrence Prognosis.

Authors:  Agata Salska; Michał Dziuba; Witold Salski; Krzysztof Chizynski; Marzenna Zielinska
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.